Terminated PHASE2 INTERVENTIONAL 5-arm NCT02971839

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Cystic Fibrosis

Interventions IVA Placebo VX-561

Updated 14 times since 2017 Last updated: Aug 11, 2020 Started: Dec 31, 2016 Primary completion: Aug 31, 2017 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Decision by Sponsor.

Other terminated trials from Vertex Pharmaceuticals Incorporated

See all terminations from Vertex Pharmaceuticals Incorporated

Other Cystic Fibrosis trials with similar outcome

Browse all Cystic Fibrosis trials

This PHASE2 trial investigates Cystic Fibrosis and is currently terminated or withdrawn. Vertex Pharmaceuticals Incorporated leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2

▶ Show 9 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2
Sep 2020 — Jan 2021 [monthly]

Terminated PHASE2
Sep 2018 — Sep 2020 [monthly]

Terminated PHASE2
Jun 2018 — Sep 2018 [monthly]

Terminated PHASE2
Oct 2017 — Jun 2018 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Sep 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2017 — Sep 2017 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vertex Pharmaceuticals Incorporated

Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Indianapolis, United States , Los Angeles, United States , Miami, United States , Morristown, United States , Palo Alto, United States , Philadelphia, United States and 4 more locations